Skip to main content

HELLO!

What is your question about?

Ordering Information

Patient Support Services

Contact an Oncology Account Manager

Contact an Access and Reimbursement Manager

Submit a Medical Information Request

How to order Defitelio® (defibrotide sodium)

McKesson Plasma and Biologics

Phone:

1-877-625-2566

Fax:

1-888-752-7626

Email:

MPBOrders@mckesson.com

Email for all other information requests:

MPB@mckesson.com
  • Orders can be placed Monday through Friday, 9 AM to 7:30 PM ET
    • Overnight delivery is available for orders placed by 7:30 PM ET
    • For emergency orders after hours of service, call 1-877-625-2566 (24/7/365)
  • Verify your institution has a contract with McKesson Plasma and Biologics before ordering; if not, contact McKesson Plasma and Biologics or your Jazz Access and Reimbursement Manager (ARM) in your territory for information about setting up an account

Patient support services

Call the patient support hotline 1-888-837-4397, Monday through Friday between 8 AM and 8 PM ET to speak with a representative.

Contact an Oncology Account Manager

Please complete the following information to contact a specialty sales consultant.

*Required field

*Please enter a valid first name.

Please enter a valid first name.

*Please enter a valid last name.

Please enter a valid last name.

*Please enter a valid email address.

Please enter a valid email address.

Please enter a valid phone number.

*Please enter a valid ZIP code.

Please enter a valid ZIP code.

*Please confirm

*Please confirm

Privacy statement

Thank you!

A Jazz representative will contact you shortly.

Jazz Pharmaceuticals respects your interest in keeping your personal information private. The personal information you provide will be used by Jazz Pharmaceuticals to respond to your request. For more information about how Jazz Pharmaceuticals protects your personal information, please click here to view our Privacy Statement.

To contact Jazz Pharmaceuticals Customer Service, please call 1-800-833-3533.

To report suspected adverse reactions, please call Jazz Pharmaceuticals at 1-800-520-5568 or contact the FDA at 1-800-FDA-1088.

Contact an Access and Reimbursement Manager

Please complete the following information to contact an access and reimbursement manager.

*Required field

*Please enter a valid first name.

Please enter a valid first name.

*Please enter a valid last name.

Please enter a valid last name.

*Please enter a valid email address.

Please enter a valid email address.

Please enter a valid phone number.

*Please enter a valid ZIP code.

Please enter a valid ZIP code.

*Please confirm

*Please confirm

Privacy statement

Thank you!

A Jazz representative will contact you shortly.

Jazz Pharmaceuticals respects your interest in keeping your personal information private. The personal information you provide will be used by Jazz Pharmaceuticals to respond to your request. For more information about how Jazz Pharmaceuticals protects your personal information, please click here to view our Privacy Statement.

To contact Jazz Pharmaceuticals Customer Service, please call 1-800-833-3533.

To report suspected adverse reactions, please call Jazz Pharmaceuticals at 1-800-520-5568 or contact the FDA at 1-800-FDA-1088.

To request medical information about DEFITELIO, visit the Jazz Pharmaceuticals Medical Information Portal.

You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.

PATHOPHYSIOLOGY OF VOD

VOD can rapidly progress from endothelial damage to death1,2

Take a closer look at the cascade of events that precedes the clinical manifestations of VOD.

liver icon

Learn more about the progressive cascade of VOD from leading experts

Watch video

Progressive cascade of VOD

hepatocyte

Hepatocytes

endothelial cell

Endothelial cells

red blood cell

Red blood cells

white blood cell

White blood cells

platelet activated

Platelets

extracellular matrix

Extracellular matrix

1 healthy sinusoid

Healthy sinusoid

Sinusoidal endothelial cells provide a barrier between the blood and hepatocytes and regulate hemostasis, permeability, vascular tone, and immune and inflammatory responses.3

Based on experimental models, buildup of toxic metabolites from conditioning regimens may trigger damage to sinusoidal endothelium.4-6

2 endothelial damage

Endothelial damage

Activation of endothelial cells triggers expression of cytokines and adhesion molecules, activating inflammatory pathways that cause additional endothelial damage.4-6 In addition, release of the enzyme heparanase contributes to degradation of the extracellular matrix, loss of cytoskeletal structure, and gap formation between sinusoidal endothelial cells.4-6

3 sinusoid narrowing

Sinusoidal narrowing

This disruption of the endothelium allows red blood cells, leukocytes, and cellular debris to move into the space of Disse. This can lead to sinusoidal narrowing and dissection of endothelial cells, which may embolize downstream and contribute to sinusoidal blockage.5,6

4 sinusoid blockage

Sinusoidal blockage

Sinusoidal endothelial cell damage also triggers the expression of multiple factors that regulate coagulation and fibrinolysis (table A).6-8 All of these events can lead to a procoagulant and hypofibrinolytic state, where fibrin deposition, clot formation, and sinusoidal narrowing can cause further blockage. This sinusoidal disruption may be associated with hepatocyte cell death.1,3,5,6

A. FACTORS THAT REGULATE COAGULATION AND FIBRINOLYSIS6-8

Factor
Function
von Willebrand factor
stimulates platelet aggregation
Tissue factor
promotes activation of factor X
Plasminogen activator inhibitor-1
reduces fibrinolysis

Clinical manifestation

The cascade of events appears to start BEFORE clear clinical and pathological manifestations are evident.5,6

cascading arrows pointing down cascading arrows pointing down

Reduction in hepatic venous outflow Post-sinusoidal hypertension4-6

Clinical manifestation of signs and symptoms may include4

  • Elevated bilirubin, hepatomegaly and/or upper right quadrant pain, weight gain, fluid retention, ascites

Multi-organ dysfunction1,5,9

  • Progressing damage may lead to renal or pulmonary dysfunction

Death1,5

  • Often due to multi-organ failure

84%

overall mortality in VOD with multi-organ dysfunction1,a

aBased on 19 studies (235 patients) that specifically determined mortality from severe VOD, as reported within a meta-analysis of 135 studies performed between 1979 and 2007.

IMPORTANT SAFETY INFORMATION AND INDICATION

Contraindications

Defitelio is contraindicated in the following conditions:

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see full Prescribing Information.

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see full Prescribing Information.

MOA=mechanism of action; VOD=veno-occlusive disease.

References: 1. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157-168. 2. Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168(4):481-491. 3. Vion AC, Rautou PE, Durand F, et al. Interplay of inflammation and endothelial dysfunction in bone marrow transplantation: focus on hepatic veno-occlusive disease. Semin Thromb Hemost. 2015;41(6):629-643. 4. Carreras E. Early complications after HSCT. In: Apperley J, Carreras E, Gluckman E, et al, eds. The EBMT Handbook. 6th ed. Paris, France: European School of Haematology; 2012:176-195. 5. Richardson PG, Ho VT, Cutler C, et al. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013;19(suppl 1):S88-S90. 6. Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013;12(1):123-136. 7. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev. 2003;17(2):63-70. 8. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005-3020. 9. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255-267.